NAD+ (1,000 mg Vial) Dosage Protocol
NAD+ is a small-molecule AMPK activator (5-aminoimidazole-4-carboxamide ribonucleotide) studied as an exercise mimetic in metabolic research.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
1000 mg strength reconstituted to 3.0 mL (333.33 mg/mL)
Community-Reported Use
| Week / Phase | Amount per Administration | U-100 Units (mL) | Frequency |
|---|---|---|---|
| Week 1 | 50 mg | 15 units (0.15 mL) | Once daily |
| Week 2 | 75 mg | 22.5 units (0.225 mL) | Once daily |
| Weeks 3–8 | 100 mg | 30 units (0.30 mL) | Once daily |
| Weeks 9–12 | 100 mg | 30 units (0.30 mL) | Once daily |
| Weeks 13–16 | 100 mg | 30 units (0.30 mL) | Once daily |
Frequency: The calculation schedule uses one administration per day. U-100 syringe units are volume markings, not peptide international units.
Four Reconstitution Steps
- Wash hands, prepare a clean work area, and clean the NAD+ vial stopper and diluent stopper with separate alcohol swabs.
- Draw 3.0 mL of bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the container.
- Gently swirl or roll the vial until the powder dissolves. Do not shake.
- Label the vial with the compound, 333.33 mg/mL concentration, and preparation date; refrigerate at 2–8°C (36–46°F) and protect from light.
Research reference only: Published human work includes a 750 mg intravenous infusion study and an observational infusion case series, not a controlled trial of this 50–100 mg calculation schedule. The rows above preserve a community-reported research pattern solely so the concentration, volume, and supply calculations can be interpreted. They are not a recommendation, standard of care, or evidence of safety or efficacy.
Important: This guide is for educational and research-reference purposes only. It is not medical advice and does not establish a human-use protocol.
DCH HERO END
Supplies Needed
Supplies Needed
Supply estimates follow the calculation schedule above and assume one new syringe plus two alcohol swabs per day.
| Item | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|
| Peptide Vials (NAD+, 1000 mg each) | 6 vials (approximately 5,075 mg calculated) | 8 vials (approximately 7,875 mg calculated) | 11 vials (approximately 10,675 mg calculated) |
| Insulin Syringes (U-100, 1 mL) | 56 syringes | 84 syringes | 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 18 mL → 2 bottles | 24 mL → 3 bottles | 33 mL → 4 bottles |
| Alcohol Swabs | 112 swabs — 2 boxes required (100 swabs each) | 168 swabs — 2 boxes required (100 swabs each) | 224 swabs — 3 boxes required (100 swabs each) |
Sharps safety: Place used needles and syringes in an FDA-cleared sharps container immediately after use; never reuse them.
Protocol Overview
NAD+ is technically a small molecule rather than a peptide. WADA prohibited list. Most research-grade use pairs with regular endurance training to amplify the AMPK-activation effects.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
NAD+ is a small molecule (not strictly a peptide) that acts as an AMP-mimetic, activating AMP-activated protein kinase (AMPK). AMPK activation drives fatty-acid oxidation, mitochondrial biogenesis, and glucose uptake in skeletal muscle — mimicking exercise-induced metabolic adaptations.
Potential Benefits & Side Effects
Potential Benefits
- Rapid increase in intracellular NAD+ levels.
- Sirtuin (SIRT1/3) activation — DNA repair, mitochondrial biogenesis.
- Studied for energy, cognition, and metabolic health.
Side Effect Profile
- Flushing, warmth, tingling during IV infusion (rate-dependent).
- Nausea, headache if administered too rapidly.
Lifestyle Factors
- IV: slow infusion (90–180 min) reduces side effects.
- Sub-Q: less flushing than IV; rotate sites.
Injection Technique
- Subcutaneous: abdomen or thigh, 90° angle, rotate sites.